相关实验视频

Updated: Sep 16, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

在癌症中准LAG-3的治疗潜力

Diwakar Davar¹, Ana Carrizosa Anderson², Ivan Diaz-Padilla³

¹Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA davard@upmc.edu.

Journal for immunotherapy of cancer

|July 9, 2025

概括

像PD-1和LAG-3这样的免疫检查点抑制剂在癌症治疗中表现有前途. 淋巴细胞激活基因3 (LAG-3) 和PD-1的双重阻断改善了晚期黑色素瘤的生存率.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症研究癌症研究

背景情况:

针对编程死亡-1 (PD-1) 的免疫检查点抑制剂和细胞毒性T淋巴细胞相关蛋白4已改善了各种固体瘤的存活率.
淋巴细胞激活基因3 (LAG-3) 是一种在耗尽的T细胞上发现的抑制受体,在调节抗瘤免疫力方面发挥作用.

研究的目的:

审查当前对LAG-3在抗瘤免疫力中的作用的理解.
总结LAG-3导向药物在癌症治疗中的临床开发状态.

主要方法:

关于LAG-3的临床前和临床研究的文献综述.
对不同类型癌症中LAG-3抑制剂的临床试验数据的分析.

主要成果:

使用relatlimab和nivolumab对LAG-3和PD-1的双重阻断表明在晚期黑色素瘤中改善了无进展生存率 (PFS),从而获得了FDA的批准.
尽管有一些负面的试验结果,但新的LAG-3定向疗法,如双特异性抗体,继续显示出潜力.

结论:

LAG-3是免疫瘤学的重要目标,双重阻断在特定癌症中显示出临床益处.
目前正在进行的研究和新的治疗策略对于最大限度地提高LAG-3抑制在癌症治疗中的潜力至关重要.

关键词:

免疫检查点抑制剂免疫检查点抑制剂免疫疗法免疫疗法这是一种单克隆抗体.

更多相关视频

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...